Given the pivotal role of the NF-κB pathway and the NLRP3 inflammasome in the pathogenesis of PD, KPT-8602 was suggested to be a promising drug for the clinical treatment of such diseases. This evidence concerns the gene NFKB1 and Parkinson disease.